BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
AstraZeneca PLC (LON:AZN) announced plans to transfer its U.S. trading venue from Nasdaq to the New York Stock Exchange (NYSE), a move designed to broaden access to global investors and enhance long-term growth opportunities. The Anglo-Swedish pharmaceutical giant emphasized that it will remain headquartered and tax resident in the United Kingdom, while continuing to maintain listings in London and Stockholm.
Following the announcement, AstraZeneca shares gained 1.5% in early London trading, reflecting investor optimism about the transition. Chair Michel Demare noted the strategic importance of the shift, explaining that a harmonized global listing structure will help support sustainable growth and provide exposure to a more diverse mix of institutional and retail investors, particularly within the U.S. market.
The decision comes amid mounting pressure on the U.K. equity market as major corporations seek higher valuations abroad. Several well-known firms, including Unilever with its ice cream business spin-off and commodities group Glencore, have explored alternatives to London. AstraZeneca’s move underscores this broader trend of companies reassessing the appeal of the London Stock Exchange.
Despite speculation earlier this year that AstraZeneca might abandon its London presence entirely, the company confirmed it remains committed to its U.K. base. However, the drugmaker has scaled back certain domestic investments, including shelving a planned £200 million expansion of its Cambridge research facility, citing challenging business conditions in the country.
Political and regulatory pressures are also influencing AstraZeneca’s global strategy. With the U.S. government taking a tougher stance on the pharmaceutical industry, including calls for greater domestic investment, AstraZeneca aims to balance market access with operational flexibility. The proposal still requires shareholder approval, with a vote scheduled for November 3.
By securing a NYSE listing while retaining its European bases, AstraZeneca is positioning itself to attract a wider pool of global investors, strengthen its market presence, and support its long-term strategy for sustainable growth.
